Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Monte Rosa Therapeutics Inc (NQ: GLUE ) 6.970 +0.640 (+10.11%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 359,493 Open 6.420 Bid (Size) 6.840 (1) Ask (Size) 7.100 (1) Prev. Close 6.330 Today's Range 6.170 - 7.000 52wk Range 2.440 - 8.840 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study August 19, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 GLUE stock results show that Monte Rosa Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Performance YTD +22.07% +22.07% 1 Month +52.52% +52.52% 3 Month +66.75% +66.75% 6 Month +9.94% +9.94% 1 Year +14.64% +14.64% More News Read More Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update August 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day July 08, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics: Q4 Earnings Insights March 14, 2024 Via Benzinga Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160 June 27, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis June 14, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Announces Leadership Team Promotions May 30, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference May 30, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease May 21, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Pre-Market Session May 16, 2024 Via Benzinga Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering May 16, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session May 15, 2024 Via Benzinga Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants May 15, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire GLUE Stock Earnings: Monte Rosa Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer May 02, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session March 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session March 26, 2024 Via Benzinga GLUE Stock Earnings: Monte Rosa Therapeutics Misses EPS for Q4 2023 March 14, 2024 Via InvestorPlace Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 14, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor March 11, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire Monte Rosa Therapeutics' AI And Machine Learning Platform Is Adding Significant Value Creation in Cancer Research: Analyst February 15, 2024 Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences January 31, 2024 From Monte Rosa Therapeutics, Inc. Via GlobeNewswire 3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street January 16, 2024 Via The Motley Fool Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
